Daily administration of L. reuteri also contributes to increased ICB efficacy in mice, in which L. reuteri facilitates the translocation of gut microbes into melanoma tumors to trigger the function of antitumor IFN-γ+ CD8+ T cells [163]. The gene discussed is CD8A; the disease is melanoma.